Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1984 Aug;26(2):268–269. doi: 10.1128/aac.26.2.268

In vitro activities of teichomycin, fusidic acid, flucloxacillin, fosfomycin, and vancomycin against methicillin-resistant Staphylococcus aureus.

S H Guenthner, R P Wenzel
PMCID: PMC284135  PMID: 6237606

Abstract

Flucloxacillin, fosfomycin, fusidic acid, teichomycin, and vancomycin were tested against 50 clinical isolates of methicillin-resistant Staphylococcus aureus by a broth macrodilution technique. Teichomycin had a narrow range of activity, similar to that of vancomycin (0.5 to 2.0 micrograms/ml). Fusidic acid had the lowest range of inhibitory activity, with 50 and 90% MICs of 0.19 and 0.35 micrograms/ml, respectively. Flucloxacillin and fosfomycin showed less activity, with MICs up to 32 micrograms/ml.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allona A., Díaz Cabrera J. A., Manchado P. Fosfomycin in chronic urinary infections. Chemotherapy. 1977;23 (Suppl 1):267–274. doi: 10.1159/000222059. [DOI] [PubMed] [Google Scholar]
  2. Anderson J. D. Fusidic acid: new opportunities with an old antibiotic. Can Med Assoc J. 1980 Apr 5;122(7):765–769. [PMC free article] [PubMed] [Google Scholar]
  3. BARBER M., WATERWORTH P. M. Antibacterial activity in vitro of fucidin. Lancet. 1962 May 5;1(7236):931–932. doi: 10.1016/s0140-6736(62)91969-4. [DOI] [PubMed] [Google Scholar]
  4. GODTFREDSEN W., ROHOLT K., TYBRING L. Fucidin: a new orally active antibiotic. Lancet. 1962 May 5;1(7236):928–931. doi: 10.1016/s0140-6736(62)91968-2. [DOI] [PubMed] [Google Scholar]
  5. Garrod L. P. Methicillin-resistant staphylococci. Lancet. 1968 Oct 19;2(7573):871–871. doi: 10.1016/s0140-6736(68)91028-3. [DOI] [PubMed] [Google Scholar]
  6. Grüneberg R. N., Emmerson A. M. Failure to prevent emergence of bacterial resistance by combination of two antibiotics: fusidic acid and rifampicin. J Antimicrob Chemother. 1980 Jul;6(4):562–564. doi: 10.1093/jac/6.4.562. [DOI] [PubMed] [Google Scholar]
  7. Hutzler R., Fernandes V., Muñoz D., Rozentraub A. Activity of fosfomycin in the treatment of bacterial infections. Chemotherapy. 1977;23 (Suppl 1):358–364. doi: 10.1159/000222076. [DOI] [PubMed] [Google Scholar]
  8. Kahan F. M., Kahan J. S., Cassidy P. J., Kropp H. The mechanism of action of fosfomycin (phosphonomycin). Ann N Y Acad Sci. 1974 May 10;235(0):364–386. doi: 10.1111/j.1749-6632.1974.tb43277.x. [DOI] [PubMed] [Google Scholar]
  9. Parenti F., Beretta G., Berti M., Arioli V. Teichomycins, new antibiotics from Actinoplanes teichomyceticus Nov. Sp. I. Description of the producer strain, fermentation studies and biological properties. J Antibiot (Tokyo) 1978 Apr;31(4):276–283. doi: 10.7164/antibiotics.31.276. [DOI] [PubMed] [Google Scholar]
  10. Pattison J. R., Mansell P. E. Fucidin-resistant staphylococci in current hospital practice. J Med Microbiol. 1973 May;6(2):235–244. doi: 10.1099/00222615-6-2-235. [DOI] [PubMed] [Google Scholar]
  11. Peacock J. E., Jr, Moorman D. R., Wenzel R. P., Mandell G. L. Methicillin-resistant Staphylococcus aureus: microbiologic characteristics, antimicrobial susceptibilities, and assessment of virulence of an epidemic strain. J Infect Dis. 1981 Dec;144(6):575–582. doi: 10.1093/infdis/144.6.575. [DOI] [PubMed] [Google Scholar]
  12. Price J. D., Harding J. W. Flucloxacillin in the treatment of infectious conditions in children. Curr Med Res Opin. 1975;3(2):77–82. doi: 10.1185/03007997509113651. [DOI] [PubMed] [Google Scholar]
  13. Rodríguez A., Gallego A., Olay T., Mata J. M. Bacteriological evaluation of fosfomycin in clinical studies. Chemotherapy. 1977;23 (Suppl 1):247–258. doi: 10.1159/000222055. [DOI] [PubMed] [Google Scholar]
  14. Thompson R. L., Fisher K. A., Wenzel R. P. In vitro activity of N-formimidoyl thienamycin and other beta-lactam antibiotics against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1982 Feb;21(2):341–343. doi: 10.1128/aac.21.2.341. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Thompson R. L., Wenzel R. P. International recognition of methicillin-resistant strains of Staphylococcus aureus. Ann Intern Med. 1982 Dec;97(6):925–926. doi: 10.7326/0003-4819-97-6-925. [DOI] [PubMed] [Google Scholar]
  16. Thornsberry C., McDougal L. K. Successful use of broth microdilution in susceptibility tests for methicillin-resistant (heteroresistant) staphylococci. J Clin Microbiol. 1983 Nov;18(5):1084–1091. doi: 10.1128/jcm.18.5.1084-1091.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Traub W. H., Kleber I. Interpretation of diffusion susceptibility data obtained with 10-mug fucidin (sodium fusidate) disks against clinical isolates of Staphylococcus aureus. Chemotherapy. 1974;20(2):92–96. doi: 10.1159/000221796. [DOI] [PubMed] [Google Scholar]
  18. Traub W. H. Variable tolerance of a clinical isolate of Staphylococcus epidermidis from an infected hydrocephalus shunt for several beta-lactam antibiotics, vancomycin and fosfomycin. Chemotherapy. 1981;27(6):432–443. doi: 10.1159/000238013. [DOI] [PubMed] [Google Scholar]
  19. Unsworth P. F., Heatley F. W., Phillips I. Flucloxacillin in bone. J Clin Pathol. 1978 Aug;31(8):705–711. doi: 10.1136/jcp.31.8.705. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Wenzel R. P. The emergence of methicillin-resistant Staphylococcus aureus. Ann Intern Med. 1982 Sep;97(3):440–442. doi: 10.7326/0003-4819-97-3-440. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES